Paper Details

  1. Home
  2. Paper Details

Schedule-dependent synergistic effects of 5-fluorouracil and selumetinib in KRAS or BRAF mutant colon cancer models.

Author: HwangJung Jin, JangHye Yeon, KimDo Hyung, KimSeog-Young, KimWon Dong, LeeHaeng Jung, LeeSeung Jin, MoonDae Hyuk

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated whether the combination of 5-FU and a MEK inhibitor had treatment sequence-dependent synergistic effects in KRAS or BRAF mutant colon cancer models. Treatment with 5-FU followed by selumetinib (FS) induced the highest cell death and synergy compared with reverse (SF) and concomitant (cFS) treatment in six cell lines. FS enhanced apoptosis and decreased anchorage-independent growth. Administration of 5-FU followed by selumetinib in colo205 and HCT8 xenograft models significantly decreased tumor growth compared with a single agent.
Paper Details　
Original Abstract of the Article :
Combination of MEK inhibitor and 5-FU had showed limited efficacy in clinical trials. We previously reported that acquired resistance to 5-FU was related with continued activation of salvage pathway. Here we investigated whether combination of 5-FU and a MEK inhibitor had treatment sequence-dependen...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.bcp.2018.12.017

データ提供：米国国立医学図書館（NLM）

Tweaking the Treatment Schedule: Optimizing 5-FU and Selumetinib for Colon Cancer

The world of [cancer] research is a constant pursuit of better therapies. This study delves into the exciting realm of [combination therapy], focusing on [5-fluorouracil (5-FU)] and [selumetinib], two drugs used to combat [colon cancer]. The researchers investigated how the timing of administering these medications could impact their effectiveness, particularly in tumors with specific mutations like [KRAS or BRAF].

Their findings revealed that a [sequential administration] approach, where [5-FU] was given followed by [selumetinib], demonstrated superior results in reducing tumor growth compared to other treatment schedules. This discovery is a significant step forward in [cancer] treatment optimization.

A Strategic Approach: Timing is Key

This research offers a compelling case for the importance of treatment timing in [cancer] therapy. The [sequential administration] of [5-FU] and [selumetinib] demonstrated a significant advantage over other approaches, suggesting that tailored schedules may be key to achieving optimal outcomes.

Hope for Personalized Therapy: A Tailored Approach to Cancer

The findings of this study offer a potential avenue for [personalized therapy], a promising approach to tailoring treatment strategies to individual patients. Understanding the importance of treatment timing in [colon cancer] could lead to more effective and targeted therapies, improving patient outcomes.

Dr. Camel's Conclusion

This research highlights the importance of considering the timing of drug administration in [cancer] treatment. The promising results observed with the sequential administration of [5-FU] and [selumetinib] offer a new strategy for combating [colon cancer], especially in cases with specific mutations. This research contributes to the growing field of [personalized therapy], where treatment is tailored to individual patient characteristics for better outcomes.

Date :
  1. Date Completed 2019-09-03
  2. Date Revised 2019-09-03
Further Info :

Pubmed ID

30579838

DOI: Digital Object Identifier

10.1016/j.bcp.2018.12.017

Related Literature

Article Analysis
・Effects of selumetinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.